Form 4: Pliant Therapeutics Director Steve Krognes Granted 30,000 Stock Options

Pliant Therapeutics, Inc. Director Steve Krognes was granted 30,000 stock options with an exercise price of $1.61, vesting over approximately one year, as disclosed in a recent SEC Form 4 filing.

Summary

• Steve E. Krognes, a Director of Pliant Therapeutics, Inc. (PLRX), was granted 30,000 derivative securities in the form of a right to buy common stock.
• The transaction date for this grant was June 5, 2025.
• The exercise price for these options is $1.61 per share.
• The options have an expiration date of June 5, 2035.
• The vesting schedule for these options is structured as follows: 25% vest on October 1, 2025; 25% vest on January 1, 2026; 25% vest on April 1, 2026; and the final 25% vest on the earlier of June 5, 2026 (one-year anniversary of grant) or the next annual meeting of stockholders.
• Vesting is contingent upon Mr. Krognes's continued service as a Director.

Sentiment

Score: 7

Explanation: The grant of stock options to a director is a positive signal for corporate governance and alignment of interests, indicating continued commitment from the board member. It's a standard compensation practice.

Positives

• The grant of stock options to Director Steve Krognes aligns his interests with those of shareholders, incentivizing long-term performance and retention.
• The exercise price of $1.61 provides a clear benchmark for future stock performance relative to the grant date.

Negatives

• No direct negative financial implications are immediately apparent from this routine insider compensation filing.

Risks

• The vesting of the options is subject to the Reporting Person's continued service to the Issuer as a Director, meaning unvested options could be forfeited if service ceases.
• The value of the options is dependent on the future market price of PLRX common stock exceeding the exercise price of $1.61.

Future Outlook

The vesting schedule indicates a commitment to retaining Director Steve Krognes through at least April 2026, with the final tranche vesting by June 2026 or the next annual meeting, subject to his continued service.

Industry Context

This Form 4 filing represents a standard equity compensation practice for directors in the biotechnology or pharmaceutical industry, aiming to align executive and board member incentives with long-term shareholder value creation.

Corporate Governance

Stakeholder Impact

• Shareholders: The option grant aligns the director's financial interests with long-term shareholder value creation, as the options gain value only if the stock price increases above the exercise price.

Next Steps

• Continued service of Steve Krognes as a Director for the options to vest.
• Future vesting events on October 1, 2025, January 1, 2026, April 1, 2026, and the earlier of June 5, 2026, or the next annual meeting of stockholders.

Key Dates

Recommendation

Keywords

Pliant Therapeutics, PLRX, Steve Krognes, Stock Options, Form 4, Insider Transaction, Director Compensation, Equity Grant, Vesting Schedule